ihc cst 4791s ab 2099709 her3 erbb3 d22c5 xp wb  (Cell Signaling Technology Inc)

Journal: medRxiv

Article Title: Localized high-risk prostate cancer harbors an androgen receptor low subpopulation susceptible to HER2 inhibition

doi: 10.1101/2024.02.09.24302395

Figure Lengend Snippet: (A) Heatmaps summarizing semi-quantitative analysis of anti-EGFR and anti-pEGFR IHC performed on entire sections of biopsies and posttreatment surgical specimens. Rows are grouped by patient. (B-E) Density plots summarizing the frequency distribution of IHC semi-quantitative analysis, per patient, of baseline biopsies ( B-C) or of posttreatment prostatectomy specimens (D-E) with antibodies against EGFR (B,D) and pEGFR (C,E) . (F) Density plots of EGFR baseline semi-quantitative IHC, stratified by pathologic response in the final surgical specimens with exceptional responders in green and incomplete/nonresponders in red. Statistical significance determined using χ-squared test. (G) Heatmaps summarizing semi-quantitative analysis of anti-HER3 and anti-pHER3 IHC performed on entire sections of posttreatment surgical specimens. (H-I) Density plots summarizing the frequency distribution of IHC semi-quantitative analysis, per patient, of posttreatment tumors with antibodies against HER3 (H) and pHER3 (I) . Inv: invasive; IDC: intraductal carcinoma; memb: membranous; cyto: cytosolic.

Article Snippet: After 10-minute incubations in Background Punisher (Biocare; BP974), 300 μL of primary antibody solutions were prepared and incubated with tissues at room temperature at 1:100 dilutions into Renoir Red diluent (Biocare Medical; PD904) for 1 h: anti-EGFR clone D38B1 (Cell Signaling; 4267), anti-pEGFR clone D7A5 (Cell Signaling; 3777), anti-HER2 clone 29D8 (Cell Signaling; 2165), anti-pHER2 clone 6B12 (Cell Signaling; 2243), anti-HER3 clone D22C5 (Cell Signaling; 12708), and anti-pHER3 clone 21D3 (Cell Signaling; 4791).

Techniques: